Thirty-two of Qualitest's products are listed among the top 250 generics by total prescription (TRx) volume. ![]() The company brings a broad range of generics to Endo encompassing 175 product families. ![]() including the ability to manufacture controlled substances, which make up approximately 40 percent of its product portfolio, and liquids, which are roughly 17 percent of its portfolio. Qualitest has cGMP facilities in the U.S. generics company as measured by prescriptions filled, is focused on cost competitive, high quality manufactured products with high barriers to entry. The combined company will deliver more comprehensive healthcare solutions across its diversified businesses in Branded Pharmaceuticals, Generics, Devices & Services in key therapeutic areas including pain and urology. Company Reiterates Full-Year 2010 Financial GuidanceĮndo Pharmaceuticals (Nasdaq: ENDP) announced today that it has entered into a definitive agreement to acquire Qualitest Pharmaceuticals, a leading, privately-held generics company in the U.S., for approximately $1.2 billion in cash. Transaction Expected to be Immediately Accretive to Adjusted DilutedĮarnings per Share by $0.40 in First Full Year After Close ![]() Diversifies Revenue Streams and Boosts Scale in Existing Genericsīusiness, and Strengthens Core Pain Franchise
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |